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The erythrocyte sedimentation rate (ESR), a commonly performed test of the acute phase response, is the rate at which erythrocytes sedi-
ment in vitro in 1 hr. The molecular basis of erythrocyte sedimentation is unknown. To identify genetic variants associated with ESR, we
carried out a genome-wide association study of 7607 patients in the Electronic Medical Records and Genomics (eMERGE) network. The
discovery cohort consisted of 1979 individuals from the Mayo Clinic, and the replication cohort consisted of 5628 individuals from the
remaining four eMERGE sites. A nonsynonymous SNP, rs6691117 (Val/IIe), in the complement receptor 1 gene (CR1) was associated
with ESR (discovery cohort p ¼ 7 3 1012, replication cohort p ¼ 3 3 1014, combined cohort p ¼ 9 3 1024). We imputed 61 SNPs in
CR1, and a ‘‘possibly damaging’’ SNP (rs2274567, His/Arg) in linkage disequilibrium (r2 ¼ 0.74) with rs6691117 was also associated
with ESR (discovery p ¼ 5 3 1011, replication p ¼ 7 3 1017, and combined cohort p ¼ 2 3 1025). The two nonsynonymous SNPs
in CR1 are near the C3b/C4b binding site, suggesting a possible mechanism by which the variants may influence ESR. In conclusion,
genetic variation inCR1, which encodes a protein that clears complement-tagged inflammatory particles from the circulation, influences
interindividual variation in ESR, highlighting an association between the innate immunity pathway and erythrocyte interactions.The erythrocyte sedimentation rate (ESR) is a commonly
performed laboratory test of the acute phase response
that was first introduced in the 1920s and was considered
a great advance at that time.1 Although the clinical utility
of ESR has diminished with the availability of direct
measurement of acute phase response proteins such as
C-reactive protein,2 it is still commonly used in clinical
practice, and extreme elevation (>100 mm/hr) is a marker
of serious underlying disease, such as infection, auto-
immune disorder, or malignancy.3,4 An elevated ESR is
associated with increased risk of coronary heart disease,
although the mechanism underlying the association is
unclear.5 Themolecular basis of erythrocyte sedimentation
is not known, although increased levels of acute phase
proteins (especially fibrinogen and immunoglobulins)1
and alterations in the size, shape, and number of red blood
cells (RBC)1 are thought to play a role. As part of the
Electronic Medical Records and Genomics (eMERGE)
network,6 we investigated whether common genetic vari-
ants are associated with RBC traits, including ESR.7
The electronicmedical record (EMR)-based genome-wide
association analyses in the eMERGE network have been
approved by the institutional review boards of the partici-
pating sites. Data for ESR, which is measured by standard-
ized assays in the clinical setting—most commonly the
Westergen method—were obtained from the EMR. In the
Westergenmethod, anticoagulated blood is allowed to sedi-
ment for 1 hr in a glass tube 200 mm in length. ESR values1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, U
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Values increase with age and are higher in women and
African Americans. Any ESR trait values obtained during
an inpatient hospitalization were excluded.
Genotyping was performed with the Illumina Human
660W-Quadv1_A genotyping platform, consisting of
561,490 SNPs and 95,876 intensity-only probes, in 17,056
patients from the five eMERGE sites, including 14,105
patients of self-reported European ancestry. DNA samples
from Mayo Clinic, Vanderbilt University Medical Center,
and Northwestern University were genotyped at the Broad
Institute’s Center for Genotyping and Analysis. DNA
samples fromMarshfield Clinic and Group Health Cooper-
ative were genotyped at the Center for Inherited Disease
Research, Johns Hopkins University. Data were cleaned
via the quality control (QC) pipeline developed by the
eMERGE Genomics Working Group.8 The process includes
evaluation of sample and marker call rates, gender
mismatch and anomalies, duplicate and HapMap concor-
dance, batch effects, Hardy-Weinberg equilibrium, sample
relatedness, and population stratification. A total of
476,395 SNPs were used for analysis on the basis of the
following QC criteria: SNP call rate > 98%, sample call
rate> 98%,minor allele frequency> 0.05, Hardy-Weinberg
equilibrium p value> 0.001, and 99.99% concordance rate
in duplicates. The first two dimensions were derived from
multidimensional decomposition analysis of the 1-IBS
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MAYO GHC MC VUMC NU
Number of patients 1979 1864 2631 743 390
Number of ESR
measurements
6914 7528 5262 1554 1834
Age (yrs) 63.4 5 10.0 77.8 5 7.2 66.0 5 12.1 53.1 5 16.3 55.6 5 13.2
Women (%) 808 (40.8%) 1106 (59.3%) 1562 (59.3%) 477 (64.2%) 232 (59.4%)
ESR (mm/h): total 13.1 5 15.0 22.1 5 18.6 23.7 5 19.0 20.8 5 21.1 22.0 5 25.8
ESR (mm/h): men 11.6 5 15.2 21.0 5 20.5 21.5 5 19.4 20.5 5 23.6 23.8 5 29.0
ESR (mm/h): women 15.3 5 14.2 22.9 5 17.1 25.2 5 18.5 21.0 5 19.6 20.7 5 23.3
Hemoglobin (g/dL): total 13.8 5 1.3 13.3 5 1.3 13.5 5 1.3 13.4 5 1.5 12.8 5 1.7
Hemoglobin (g/dL): men 14.2 5 1.3 13.7 5 1.4 14.0 5 1.4 14.0 5 1.7 13.1 5 2.0
Hemoglobin (g/dL):
women
13.2 5 1.1 13.0 5 1.1 13.1 5 1.1 13.1 5 1.2 12.6 5 1.4
MAYO, Mayo Clinic; GHC, Group Health Cooperative; MC, Marshfield Clinic; VUMC, Vanderbilt University Medical Center; NU, Northwestern University. Age,
ESR, and hemoglobin data are shown as means 5 standard deviation.Samples greater than six standarddeviations fromthemean
of self-reportedWhite ancestry on dimensions 1 and 2were
excluded. After QC steps, 7607 patients (with 23,092 ESR
values) were available for association analyses. The charac-
teristics of this cohort are summarized in Table 1 (also see
Figure S2, available online, for distribution of ESR by site).
The lower mean ESR in the Mayo Clinic cohort could be
partly attributed to a higher proportion of men in this
cohort, the ESR being lower in men on average.
When multiple measurements of ESR were available for
an individual patient, we chose the median ESR, which
was subjected to natural logarithm transformation to
reduce skewness, prior to genetic analyses. We used an
efficient mixed-model association expedited (EMMAX)
algorithm9 to correct for sample relatedness and cryptic
population substructure. In this model, the IBS matrix
was calculated for each pair of individuals with the use of
the genome-wide genotype data, then the generalized
least-squares F-test was used to estimate the regression
coefficient (b) after adjustment for covariates. Because of
sex differences in ESR, we also assessed genotype-sex inter-
actions by using PLINK.10 No such interactions were
present; therefore, analyses were not stratified by sex.
A three-step experimental design was used to conduct
a genome-wide association study (GWAS) for ESR. We
assigned theMayoClinic cohort (n¼ 1979) as the discovery
cohort and patients from the other four sites (n ¼ 5628) as
the replication cohort. We performed a GWAS for (natural
logarithm transformed) ESR in the discovery cohort, then
in the replication cohort, and finally, we performed a joint
analysis that included all patients. Adjustment variables
included age, sex, and site, as well as hemoglobin level,
because ESR is inversely related to hemoglobin level.11
Our power was 0.49, 1, and 1, for detecting a quantitative132 The American Journal of Human Genetics 89, 131–138, July 15, 2trait locus that explained 1.5% variance in the discovery
cohort (n ¼ 1979), the replication cohort (n ¼ 5628), and
the entire cohort (n ¼ 7607), respectively, at a significance
level of 5 3 108.
The Manhattan and quantile-quantile plots summa-
rizing the results of genetic association analyses for ESR
are shown in Figure 1. Five common SNPs in complement
receptor 1 gene (CR1 [MIM 120620]) were associated with
ESR in the discovery cohort at a genome-wide significance
level, and the SNPs were replicated in patients from the
four remaining eMERGE sites (Table 2). Of the five SNPs
associated with ESR, one was a nonsynonymous SNP
(rs6691117, Ile/Val; p ¼ 7 3 1012 and p ¼ 3 3 1014
in the discovery and replication cohorts, respectively).
The minor allele G was associated with lower ESR. When
we combined the cohorts in a joint analysis, the signifi-
cance level increased (p ¼ 93 1024; Table 2). We imputed
61 additional SNPs (MAF R 0.05 and p value for HWE R
0.001) in CR1 (5 5 kb) on the basis of the phased
chromosome 1 from the HapMap II (release 21) CEU
population (Utah residents with ancestry from northern
and western Europe), using MACH1.12 The imputation
qualities (i.e., the average posterior probability for the
most likely genotype) and R2 (the squared correlation
between imputed and true genotypes) of the 61 imputed
SNPs in CR1 were 0.98 and 0.95, respectively. Imputa-
tion-based association analysis indicated that the G allele
in the ‘‘possibly damaging’’ SNP rs2274567 (His/Arg)
was associated with lower ESR in the discovery cohort
(p ¼ 5 3 1011), the replication cohort (p ¼ 7 3 1017),
and the combined cohort (p ¼ 2 3 1025). The pattern of
linkage disequilibrium (LD) and negative logarithm of
p values for CR1 SNPs associated with ESR are shown in
Figure 2, demonstrating that the five significant genotyped011
Figure 1. Manhattan and Quantile-Quantile Plots for Genome-wide Association Analysis of ESR in the Entire Cohort
The vertical axis indicates (–log10 transformed) observed P values, and the horizontal line indicates the genome-wide significance level
of p ¼ 5 3 108. In the quantile-quantile (QQ) plot, the horizontal axis shows (–log10 transformed) expected p values, and the vertical
axis indicates (–log10 transformed) observed p values.SNPs and rs2274567 are located in a single LD block of
~125 kb. Haplotype-based association analysis based on
11 genotyped SNPs revealed that six specific haplotypes








MAFb bc p Value MAF b p Value MAF
Discovery
MAYO (n ¼ 1979) 0.19 0.23 2 3 1011 0.19 0.23 5 3 1011 0.22
Replication
GHC (n ¼ 1864) 0.18 0.16 1 3 1006 0.18 0.17 4 3 1007 0.21
MC (n ¼ 2631) 0.18 0.14 1 3 1008 0.18 0.14 3 3 1008 0.21
VUMC (n ¼ 743) 0.19 0.21 9 3 1004 0.19 0.21 2 3 1003 0.22
NU (n ¼ 390) 0.22 0.22 0.013 0.21 0.24 0.008 0.24
Total (n ¼ 5628) 0.18 0.16 4 3 1017 0.18 0.16 3 3 1017 0.21
Combined
(n ¼ 7607) 0.18 0.18 3 3 1026 0.18 0.18 8 3 1026 0.22
a MAYO, Mayo Clinic; GHC, Group Health Cooperative; MC, Marshfield Clinic; V
b MAF, minor allele frequency.
c The b is the effect size of the major allele.
d The first allele is the minor allele, and the number indicates the physical locatio
The AmBecause ESR can be affected by a wide array of medical
conditions, we developed an algorithm based on billing
codes and natural language processing (NLP) of unstruc-






b p Value MAF b p Value MAF b p Value
0.22 1 3 1011 0.22 0.23 7 3 1012 0.42 0.21 4 3 1013
0.16 3 3 1007 0.20 0.17 2 3 1007 0.39 0.15 2 3 1008
0.10 2 3 1005 0.21 0.10 2 3 1005 0.41 0.10 4 3 1008
0.18 3 3 1003 0.22 0.17 6 3 1003 0.39 0.16 3 3 1003
0.21 0.016 0.24 0.20 0.019 0.45 0.18 0.012
0.14 2 3 1014 0.21 0.14 3 3 1014 0.41 0.13 2 3 1018
0.16 8 3 1024 0.21 0.16 9 3 1024 0.41 0.15 5 3 1028
UMC, Vanderbilt University Medical Center; NU, Northwestern University.
n of the SNP (NCBI 36).
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Figure 2. Regional Plot of CR1 Association with ESR
The top panel shows the association of CR1 SNPs (both genotyped and imputed) with ESR. Different colors represent LD (r2) between
rs6691117 and other SNPs. The LD (r2) is 0.74 between the nonsynonymous SNPs rs6691117 and rs2274567 (labeled with arrows).
Different point characters indicate different functional classes: ;, nonsynonymous; C, intronic or intergenic; @, conserved in
mammals. The bottom panel indicates the gene structure of CR1.comorbidities, medications, or recent blood loss (Fig-
ure S1).7 We compiled the International Classification of
Disease 9 Clinical Management (ICD-9 CM), procedural
ICD-9, and Current Procedural Terminology (CPT-4) codes
for hematologic and solid-organ malignancies, bone
marrow and solid-organ transplantation, cirrhosis, heredi-
tary anemias, malabsorption disorders, connective-tissue
disorders, inflammatory bowel disease, chronic infectious
diseases, and surgical procedures associatedwith significant
blood loss. The medications included chemotherapeutic
and immunosuppressive drugs. To validate the above
algorithm, we randomly chose 50 ESR values that were
included on the basis of the algorithm and 50 that wereTable 3. Additional SNPs Associated with ESR in the Replication and
SNP Chr Physical Position Gene Class
Dis
ba
rs1043879 1p36 25442668 C1orf63 nonsyn 0
rs3091242 1p36 25547372 TMEM50A intronic 0
rs873308 1p36 25631242 TMEM57 intronic 0
rs10903129 1p36 25641524 TMEM57 intronic 0
rs7527798 1q32.2 205938913 CR1L intronic 0
Chr, chromosome; nonsyn, nonsynonymous.
a The b is the effect size of the major allele.
134 The American Journal of Human Genetics 89, 131–138, July 15, 2excluded. The algorithm correctly included all 50 and
correctly excluded 49 out of 50 values. We then exported
the algorithm to the other eMERGE sites to extract ESR
values from the EMR. The algorithm led to the exclusion
of 2358 patients. In the remaining 5249 patients, the five
common SNPs in Table 2 remained significant although
the significance levels decreased (Table S1). The CR1 SNPs
were associated with ESR in the excluded patients (n ¼
2358) at a lower significance level (p ¼ 1 3 105).
We noted five additional SNPs that were associated with
ESR in the replication or combined cohorts (Table 3), in-
cluding four SNPs in LD on chromosome 1p36—a non-
synonymous SNP (rs1043879,Glu/Gly) in chromosome1Combined Cohorts
covery Cohort Replication Cohort Entire Cohort
p Value b p Value b p Value
.09 2 3 1003 0.10 3 3 1008 0.09 2 3 1009
.12 6 3 1006 0.10 7 3 1010 0.10 2 3 1013
.11 7 3 1005 0.10 4 3 1010 0.10 1 3 1012
.11 5 3 1005 0.10 2 3 1010 0.10 5 3 1013
.11 3 3 1004 0.09 1 3 1006 0.10 2 3 1009
011
Figure 3. Role of CR1 in Clearing Opson-
ized Immune Particles, Erythrocyte
Rosetting, and Rouleaux Formation
Pfemp-1: P. falciparum erythrocyte mem-
brane protein 1.open reading frame (C1orf63), an intronic SNP (rs3091242)
in transmembrane protein 50A (TMEM50A), and two in-
tronic SNPs (rs873308 and rs10903129) in transmembrane
protein 57 (TMEM57)—and one intronic SNP (rs7527798)
in complement receptor 1-like (CR1L) on chromosome
1q32. The functions of TMEM50A and TMEM57 are
unknown, but the proteins have transmembrane domains,
supporting the view that these integral membrane proteins
could influence erythrocyte interactions. Of note, CR1L
encodes a transmembrane protein, is in proximity to CR1,
and is expressed in hematopoietic and fetal lymphoid
tissue.13
CR1, also known as erythrocyte complement compo-
nent (3b/4b) receptor 1, CD35, or immune adhesion
receptor, is a member of the receptors of complement
activation (RCA) family that spans 21.45 cM on chromo-
some 1q32, contains more than 60 genes of which 15
are complement-related genes, and is thought to have
evolved as a result of a series of gene-duplication events.14
CR1 encodes a monomeric single-pass type I membrane
glycoprotein found on a variety of cells, including erythro-
cytes. The primary role of CR1 is to prevent immune
complex deposition in the vessel wall by binding comple-
ment-tagged inflammatory particles and facilitating their
clearance (Figure 3).15,16
CR1 is organized in tandem structural units called short
consensus repeats (SCRs)17 that are grouped into four long
homologous repeats (LHR-A to LHR-D) (Figure S3). EachThe American Journal of HumanSCR consists of 60–70 amino acids
that are highly conserved (Fig-
ure S4).18,19 The location of the non-
synonymous SNPs rs2274567 and
rs6691117 within the three-dimen-
sional structure of CR1 (PDB 2Q7Z)
is shown in Figure S2.20 The nonsy-
nonymous SNP rs6691117 is located
within the conserved b sheet (b2) of
the 25th SCR domain (LHR-C) and
changes an isoleucine residue to
valine (Figure S2 and Figure S3). The
(imputed) nonsynonymous SNP
rs2274567 is located in the conserved
b sheet (b2) of the 19
th SCR (LHR-B)
(see Figure S3 and Figure S4) and
results in change from histidine to
arginine. We hypothesize that the
nonsynonymous SNPs rs6691117
and/or rs2274567 may alter the
secondary structure of one of the
sheets (b2) thereby affecting the bind-ing affinity of CR1 to C3b and/or C4b. When C3b or C4b
binds to CR1, it induces clustering of CR1 and its subse-
quent complex formation with a scaffolding protein, Fas-
associated phosphatase 1 (FAP-1), resulting in an increase
in erythrocyte membrane deformability.21,22 Thus, altered
binding of circulating complement-opsonized particles to
RBC CR1 may in turn influence ESR (Figure 3).
PolyPhen-223 and SNPeffect24 databases were used
to elucidate the potential functional consequences of
the nonsynonymous SNPs rs6691117 and rs2274567.
PolyPhen-2, a tool that predicts the possible impact of
anaminoacidsubstitutiononthestructureandfunctionofa
human protein by using physical and comparative consid-
erations, predicted the nonsynonymous SNP rs2274567 to
be ‘‘probably damaging’’ and rs6691117 to be ‘‘benign.’’
SNPeffect indicated that rs6691117 may affect Hsp70
binding, which could affect the folding of CR1 and thereby
affect structural stability and induce changes in functions
mediated by subsequent protein-protein interactions.
To assess whether soluble CR1 levels in the serum
differed by genotypes at SNPs rs6691117 and rs2274567,
we measured CR1 levels by ELISA (USCN Life Science,
Wuhan, China) in 50 patients with the genotype GG at
rs669117 and 50 age- and sex-matched patients with geno-
types AA and AG at that SNP. All standards and patient
samples were assayed in duplicate. The limit of detection
with the use of this assay was 0.014 ng/ml. In interassay
precision testing, the mean of the low control wasGenetics 89, 131–138, July 15, 2011 135
57.2 ng/ml (coefficient of variation ¼ 15.3%) and the
mean of the high control was 90.8 ng/ml (coefficient of
variation ¼ 10.7%). Intraassay precision for the low and
high controls was 13.1% and 7.3%, respectively. We did
not find soluble serum CR1 levels to differ by genotypes
at rs6691117 (GG ¼ 69.4 5 21.7 ng/ml, AG ¼ 69.4 5
24.7 ng/ml, and AA ¼ 69.5 5 18.4 ng/ml; n ¼ 50 each;
p ¼ 0.99) or at rs2274567 (GG ¼ 68.1 5 21.4 ng/ml,
AG ¼ 70.1 5 25.1 ng/ml, and AA ¼ 69.8 5 18.2 ng/ml;
n ¼ 40, 54, and 56, respectively; p ¼ 0.77).
CR1 is known to mediate a variety of molecular func-
tions and biological processes.18,19 Gene Ontology (GO)
annotations of proteins interacting with CR1 revealed
these to be involved in protein binding, signal transduc-
tion, receptor activity, and enzyme regulator activity, as
well as the biological processes of cell communication
and cell differentiation (Figure S5). Membrane-comple-
ment regulatory proteinsmodulate tissue injury in autoim-
mune and inflammatory diseases.25,26 CR1 mediates
inhibitory signals in human lymphocytes and has emerged
as a candidate gene26 for susceptibility to immune and/or
inflammatory disorders.27,28 Gene expression studies
indicate that CR1 is significantly upregulated in malaria,
acute lymphoblastic leukemia, and Duchenne muscular
dystrophy. In mice, knocking out the ortholog of CR1
affects embryogenesis and immune, reproductive, and
renal and/or urinary systems.29,30 A two-SNP (rs6656401
and rs3818361) haplotype (AA) in CR1 was associated
with Alzheimer disease (OR ¼ 1.22, p ¼ 3E-10) in a
GWAS.31 However, these two intronic SNPs were not
strongly associated with ESR in the present study (p ¼
0.003 and p ¼ 0.0005 for rs6656401 and rs3818361,
respectively), and it is likely that different variants in
CR1 may be associated with different phenotypes.
Whether CR1 variants affect erythrocyte interactions
in vivo needs additional investigation. CR1, by binding
P. falciparum erythrocyte membrane protein-1 (PfEMP-1),32
leads to erythrocyte rosette formation in cerebral malaria,
a phenomenon that may be dependent on CR1 copy
number (Figure 3).27 Genes that mediate cyto-adherence
by P. falciparum-infected erythrocytes, such as CR1, might
exhibit signatures of natural selection.33,34 In support
of this hypothesis, up to 80% of the population of a malari-
ous region of Papua New Guinea have a high frequency
of the derived (G) allele of the nonsynonymous SNP
rs2274567,35 suggestive of recent positive selection. The
frequency of the derived G allele of the imputed non-
synonymous SNP rs2274567 was not high (0.19) in our
cohort; however, extended haplotype homozygosity
(EHH) analysis36 indicated that the overall EHH of the
derivedG allele decayedmore slowly than that of the ances-
tral allele (Figure S6). Additional studies are needed to
confirm whether natural selection has operated on CR1 in
various geographic locales.
In conclusion, several common SNPs in CR1were associ-
ated with interindividual variation in ESR, suggesting that
CR1 is involved in the molecular mechanisms that deter-136 The American Journal of Human Genetics 89, 131–138, July 15, 2mine erythrocyte sedimentation. CR1 plays a key role in
immune recognition and clearance of immune complexes
and complement-opsonized particles from the circulation.
Two nonsynonymous SNPs (rs2274567 and rs6691117)
associated with ESR may cause conformational changes
in CR1 that could affect its ability to bind C3b and/or
C4b. Our findings indicate that a complement receptor
protein that has a role in innate immunity also influences
erythrocyte interactions.Supplemental Data
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found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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